This week’s newsletter covers the latest in psychedelic research and journalism, from psilocybin’s potential to foster ecological awareness to new findings on clinical trial methodology, eating disorders, public perceptions, and phantom limb pain relief.
Noteworthy Read
How Psilocybin Can Save the Environment (Nautilus)
“To preserve nature, we need to open our minds to it.” This enlightening essay explores the potential of psilocybin and other psychedelics to shift human consciousness toward greater ecological awareness, suggesting that psychedelic experiences may foster pro-environmental behavior and deeper connection to nature.
Read more
View more in Psychedelics
More Noteworthy Reading
Everyone I Don’t Like Is Psymposia (Chemical Poetics)
In this essay, Nese Devenot responds to The New York Times‘ coverage of MAPS and the broader psychedelic movement, criticizing how the outlet leaned heavily on Psymposia’s framing without adequately vetting its claims. Devenot, a former collaborator with Psymposia, argues that the group’s scorched-earth activism often undermines nuanced discourse and reflexively targets institutions like MAPS.
Read more
View more in Psychedelics
Antidepressant Effects of Psychedelics May Be Overstated in Some Clinical Trials (PsyPost)
A new analysis suggests that some studies on psychedelic-assisted therapy may overstate antidepressant effects due to methodological issues like small sample sizes and placebo challenges.
Read more
View more in Psychedelics
Research Round-Up
Psychedelics and Eating Disorders (ACS Publications)
This review highlights emerging evidence on the use of psychedelics in treating eating disorders, noting early promise but calling for more rigorous, targeted research to evaluate efficacy and safety.
Read more
View more in Psychedelics
Perceptions of Psychedelic Use by Adults in the U.S.: Psychospiritual Benefits and Risks (APA Psych Articles)
A national survey assesses U.S. adults’ views on psychedelic use, finding widespread belief in their psychospiritual benefits alongside concern about mental health risks and social stigma.
Read more
View more in Psychedelics
Psilocybin and Phantom Limb Pain (Project CBD)
This article delves into a compelling case study highlighting the potential of psilocybin to alleviate phantom limb pain through neuroplasticity. The subject, Albert Yu-Min Lin, a UCSD researcher and National Geographic explorer, experienced significant relief from chronic phantom limb pain following a combination of psilocybin administration and mirror visual feedback therapy.
Read more
View more in Psychedelics
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to bring you in-depth coverage of the plant medicine research shaping our world. We’re grateful for every one of you.
